EBR Systems is due for approval of their Wise CRT on or before April 12 (Alllegedly (have to say that after the OPT results))
There doesn't seem to be too much interest for EBR on here, they have almost doubled in share price over the past 3-4 months leading into approval,
Their Wise CRT doesn't compete directly against current options, it offers a leadless left ventricle pacing solutions where lead based have failed.
Looks to be a good longterm opportunity if they can pull it off with potential to expand to being the primary option for treatment rather than the backstop when lead based solutions have too many issues.
Have fumbled round with some valuation estimates but they haven't put too much info forward to work with and I think they are targeting a slower rollout focused on places that have been involved with trials.
Interesting with this one it appears to be more physician led rather than hey we have a new product that's better than the others please buy it.
Anyone have any thoughts on this as far as potential valuation based around the upcoming launch?
Disc Held RL & SM